PET/MRI Imaging in sIBM/PM

• Research type

  Research Study

• Full title

  Muscle amyloid positron emission tomography and magnetic resonance imaging techniques in myositis: A feasibility evaluation

• IRAS ID

  177378

• Contact name

  Hector Chinoy

• Contact email

  hector.chinoy@manchester.ac.uk

• Sponsor organisation

  The University of Manchester

• Duration of Study in the UK

  2 years, 0 months, 1 days

• Research summary

  RELEVANCE AND IMPORTANCE
  Sporadic Inclusion Body Myositis (sIBM) is a rare but severely disabling wasting muscle disease. Unlike other forms of myositis, sIBM has no effective treatment.

  Making the diagnosis of sIBM is difficult, particularly where attempting to differentiate from Polymyositis (PM; another form of myositis). Currently clinicians rely on clinical evaluation of the patient and the findings on muscle biopsy. Unfortunately, characteristic changes are often only evident late in the disease process.

  This has two major implications. Firstly, early diagnostic uncertainty can mean that patients are unnecessarily exposed to the risks associated with the use of immunosuppressive medication (which are used to treat PM but have no effect in sIBM). Secondly, even if a disease modifying therapy were available for sIBM, it is very unlikely to derive any benefit if administered late in the disease process, when irreversible muscle damage has already occurred (i.e. as a result of delayed diagnosis).

  The development of a technique that can support earlier differentiation between sIBM and PM without the need for a muscle biopsy is desirable.

  RESEARCH AIM
  To evaluate the feasibility and usefulness of an imaging technique that combines Amyloid Positron Emission Tomography/Computed Tomography (amyloid-PET/CT) and Magnetic Resonance Imaging (MRI) muscle scans in patients with sIBM and PM. Data from the scans will be analysed and unique features that might help differentiate between the two conditions will be investigated.

  PARTICIPANTS
  A target of ten patients with sIBM and a disease control group of ten patients with Polymyositis (PM) will be recruited from specialist muscle disease clinics at Salford Royal NHS Foundation Trust

  INVOLVEMENT
  Participants will attend for two visits over an approximately four week period:

  VISIT A: Clinical assessment of disease activity/severity (includes a blood sample for those with PM) and the amyloid-PET/CT muscle scan. Wolfson Molecular Imaging Centre
  VISIT B: MRI muscle scan. NIHR Manchester Musculoskeletal Biomedical Research Unit

• REC name

  North West - Greater Manchester West Research Ethics Committee

• REC reference

  15/NW/0547

• Date of REC Opinion

  15 Jul 2015

• REC opinion

  Favourable Opinion